Effect of acute ethanol administration upon hepatic regeneration.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
W O Frank
Publications and source records attributed to W O Frank.
The efficacy of cimetidine in the treatment of "resistant" duodenal ulcers.
In a prospective multicenter trial, 43 patients with acute duodenal ulcers unhealed after four weeks of treatment with an H2-receptor antagonist, ranitidine, were switched to treatment with another H2-receptor antagonist, cimetidine. Sixty-eight percent of the unhealed patients were successfully healed; of these patients, 81% were free of daytime pain and 89% were free of nighttime pain. Of those with residual pain, 71% and 50% showed improvement in daytime and nighttime pain severity, respectively. There were no unexpected adverse reactions reported or clinically significant changes in laboratory values measured during the study. It is concluded that cimetidine is highly effective both in healing duodenal ulcers unresponsive to ranitidine therapy and in providing continued relief of daytime and nighttime pain.
Adult↗
Once-daily bedtime dosing regimen of cimetidine in the treatment of gastric ulcer.
In a double-blind study of 163 patients with benign chronic gastric ulcer, 83 were randomly assigned to receive 800 mg of cimetidine once daily at bedtime for six weeks and 80 received placebo. After six weeks of treatment, the ulcers were healed in 76% of the cimetidine-treated patients and in 55% of the placebo group (P less than 0.003). Within two weeks of starting cimetidine treatment, over 60% of the patients were without daytime or nighttime pain. At six weeks. 77% of the cimetidine-treated patients and 67% of the placebo group were without daytime pain and 89% and 74% (P less than 0.05), respectively, were without nighttime pain. The proportion of pain-free nights and days increased each week in the cimetidine-treated patients. Transient and self-limited adverse experiences were reported by 13% of the cimetidine-treated patients and by 15% of the placebo group. The results achieved in the present study with a once-daily, bedtime dose of cimetidine are similar to those seen in patients given cimetidine twice and four times daily.
Adolescent↗
Efficacy of once-daily cimetidine in preventing recurrence of duodenal ulcer.
In a prospective multicenter trial, 88 patients with acute duodenal ulcers that were healed with ranitidine were randomly assigned to receive maintenance treatment with either cimetidine 400 mg (n = 45) or placebo (n = 43) at bedtime for six months. Ten percent of the patients experienced moderate or severe pain both during the day and at night while on placebo during the maintenance phase. The average proportion of cimetidine patients experiencing moderate or severe pain during the day or night was 50% and 80% lower than placebo, respectively. Ulcer-like symptoms prompted endoscopy in 44% (19 of 43) of the placebo patients compared with 18% (eight of 45) of patients receiving cimetidine (P = 0.009). At the completion of the maintenance study, cumulative symptomatic ulcer recurrence rates were 28% (12 of 43) for those on placebo compared with 13% (six of 45) for cimetidine patients. The adverse drug effects noted were similar between treatment groups, with no unexpected reactions reported. A low dose of cimetidine (400 mg) at bedtime effectively reduced the incidence of gastrointestinal symptoms that were severe enough to prompt endoscopy as well as the actual recurrence of ulcers in those patients who had responded to initial therapy with ranitidine, but who continued to be at increased risk of reulceration.
Adult↗